Algert Global LLC Has $347,000 Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Algert Global LLC boosted its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 78.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,603 shares of the company’s stock after purchasing an additional 8,156 shares during the period. Algert Global LLC’s holdings in Kiniksa Pharmaceuticals were worth $347,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Hhlr Advisors LTD. bought a new position in shares of Kiniksa Pharmaceuticals during the first quarter worth about $61,868,000. Vanguard Group Inc. boosted its position in Kiniksa Pharmaceuticals by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 2,981,894 shares of the company’s stock worth $58,833,000 after acquiring an additional 16,595 shares during the last quarter. Rubric Capital Management LP grew its stake in shares of Kiniksa Pharmaceuticals by 10.2% during the 2nd quarter. Rubric Capital Management LP now owns 2,419,103 shares of the company’s stock worth $45,165,000 after acquiring an additional 223,094 shares in the last quarter. Granahan Investment Management LLC raised its holdings in shares of Kiniksa Pharmaceuticals by 35.2% in the fourth quarter. Granahan Investment Management LLC now owns 722,388 shares of the company’s stock valued at $12,671,000 after purchasing an additional 188,174 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Kiniksa Pharmaceuticals by 31.2% in the second quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company’s stock worth $12,398,000 after purchasing an additional 157,741 shares in the last quarter. 53.95% of the stock is currently owned by institutional investors.

Kiniksa Pharmaceuticals Price Performance

Kiniksa Pharmaceuticals stock opened at $24.47 on Wednesday. The company’s 50-day moving average is $25.37 and its 200-day moving average is $21.61. The firm has a market capitalization of $1.74 billion, a PE ratio of 222.45 and a beta of 0.33. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $14.12 and a fifty-two week high of $27.92.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, July 23rd. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.03. Kiniksa Pharmaceuticals had a negative return on equity of 7.79% and a negative net margin of 3.10%. The firm had revenue of $108.30 million for the quarter, compared to analyst estimates of $90.60 million. During the same quarter in the prior year, the company earned ($0.02) earnings per share. The business’s revenue for the quarter was up 51.5% compared to the same quarter last year. As a group, analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.29 EPS for the current year.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,500 shares of the company’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $26.91, for a total value of $470,925.00. Following the transaction, the chief operating officer now directly owns 119,911 shares in the company, valued at $3,226,805.01. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, COO Eben Tessari sold 17,500 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $26.91, for a total value of $470,925.00. Following the transaction, the chief operating officer now owns 119,911 shares of the company’s stock, valued at approximately $3,226,805.01. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Mark Ragosa sold 24,248 shares of the stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $24.79, for a total value of $601,107.92. Following the transaction, the chief financial officer now owns 19,253 shares in the company, valued at approximately $477,281.87. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 278,064 shares of company stock valued at $7,165,254 in the last quarter. 54.57% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research analysts recently weighed in on KNSA shares. Jefferies Financial Group initiated coverage on shares of Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They issued a “buy” rating and a $40.00 target price for the company. Wedbush lifted their target price on Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an “outperform” rating in a research report on Tuesday, July 23rd. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $33.60.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.